|Home||» Products||» Antidiabetic Hypoglycemic Drugs||» Insulet GN|
Insulin Glargine (rDNA)
Insulet GN (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. It is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent and is produced by recombinant DNA technology.
The primary activity of insulin glargine, is the regulation of glucose metabolism. Insulin glargine lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat tissue, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis. Insulin glargine is a human insulin analog that has been designed to have low aqueous solubility at neutral pH but high water solubility at acidic pH (pH 4). After injection into the subcutaneous tissue, the acidic solution is neutralized, leading to formation of microprecipitates from which small amounts of insulin glargine are slowly released, resulting in a relatively constant concentration/time profile over 24 hours with no pronounced peak.